

Amendments to the Claims:

1. (Currently Amended) A Modified Vaccinia Ankara Virus vaccine vector which comprises a DNA construct which comprises DNA encoding one or more human cytomegalovirus proteins selected from the group consisting of pp65, pp150, IE1, gB and antigenic fragments thereof, wherein ~~each~~ at least one of said human cytomegalovirus proteins or antigenic fragments thereof individually optionally is modified by N-terminal ubiquitination, N-end modification or both, and wherein said human cytomegalovirus protein or antigenic fragment thereof optionally contains a lysine-containing adapter sequence.
2. (Original) A protein encoded by the DNA construct of claim 1.
3. (Cancel).
4. (Original) A vaccine virus vector of claim 3 which is vaccinia virus.
5. (Cancel).
6. (Currently Amended) A Modified Vaccinia Virus vaccine vector which comprises DNA encoding one or more human cytomegalovirus proteins selected from the group consisting of pp65, pp150, IE1, gB and antigenic fragments thereof, wherein ~~each~~ at least one of said human cytomegalovirus proteins or antigenic fragments thereof individually optionally is modified by N-terminal ubiquitination, N-end modification or both, and wherein said

human cytomegalovirus protein or antigenic fragment thereof optionally contains a lysine-containing adapter sequence.

7. (Original) A Modified Vaccinia Virus vaccine vector of claim 6 which comprises Ub-R-pp65, Ub-R-pp150, Ub-R-IE1(4) and gB(s).

8. (Original) A method of vaccinating a person in need thereof against human cytomegalovirus which comprises administering to said person an effective amount of the construct of claim 1.

9. (Previously Presented) A method of vaccinating a person in need thereof against human cytomegalovirus which comprises administering to said person an effective amount of the vaccine virus vector of claim 3.

10. (Original) A method of augmenting immunity against human cytomegalovirus in a person in need thereof which comprises administering to said person an effective amount of the construct of claim 1.

11. (Previously Presented) A method of augmenting immunity against human cytomegalovirus in a person in need thereof which comprises administering to said person an effective amount of the vaccine virus vector of claim 3.

12. (Previously presented) A DNA construct of claim 1 which comprises DNA encoding:

(a) ubiquitinated, -terminal arginine, phosphokinase-deleted pp65;

(b) ubiquitinated, N-terminal arginine pp150;

- (c) ubiquitinated, N-terminal arginine IE1 exon 4; and
- (d) transmembrane domain-deleted gB.

13. (Previously Presented) A method of vaccinating a person in need thereof against human cytomegalovirus which comprises administering to said person an effective amount of the vaccine virus vector of claim 6.

14. (Previously Presented) A method of augmenting immunity against human cytomegalovirus in a person in need thereof which comprises administering to said person an effective amount of the vaccine virus vector of claim 6.

15. (New) A Modified Vaccinia Virus vaccine vector which comprises the DNA constructed in claim 12.